HRP20100276T1 - Gaboksadol za liječenje depresije i drugih afektivnih poremećaja - Google Patents
Gaboksadol za liječenje depresije i drugih afektivnih poremećaja Download PDFInfo
- Publication number
- HRP20100276T1 HRP20100276T1 HR20100276T HRP20100276T HRP20100276T1 HR P20100276 T1 HRP20100276 T1 HR P20100276T1 HR 20100276 T HR20100276 T HR 20100276T HR P20100276 T HRP20100276 T HR P20100276T HR P20100276 T1 HRP20100276 T1 HR P20100276T1
- Authority
- HR
- Croatia
- Prior art keywords
- gaboxadol
- treating depression
- pharmaceutical composition
- oral dose
- affective disorders
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims abstract 10
- 229950004346 gaboxadol Drugs 0.000 title claims abstract 10
- 208000019022 Mood disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Primjena gaboksadola kao monoterapije, naznačena time što se koristi za pripremu farmaceutske kompozicije za liječenje depresije, pri čemu farmaceutska kompozicija sadrži od 2.5 mg do 20 mg, kao što je 5 mg do 15 mg gaboksadola. Patent sadrži još 6 patentnih zahtjeva.
Claims (7)
1. Primjena gaboksadola kao monoterapije, naznačena time što se koristi za pripremu farmaceutske kompozicije za liječenje depresije, pri čemu farmaceutska kompozicija sadrži od 2.5 mg do 20 mg, kao što je 5 mg do 15 mg gaboksadola.
2. Primjena prema patentnom zahtjevu 1, naznačena time što je gaboksadol u obliku kisele adicijske soli, hidrata amfoternog iona ili anhidrata amfoternog iona.
3. Primjena prema bilo kojem od patentnih zahtjeva 1-2, naznačena time što je gaboksadol u obliku farmaceutski prihvatljive kisele adicijske soli izabrane od klorovodične ili bromovodične soli, ili u obliku monohidrata amfoternog iona.
4. Primjena prema bilo kojem od patentnih zahtjeva 1-3, naznačena time što je gaboksadol u obliku oralne doze.
5. Primjena prema bilo kojem od patentnih zahtjeva 1-4, naznačena time što je gaboksadol u obliku čvrste oralne doze, kao što su tablete ili kapsule, ili u obliku tekuće oralne doze.
6. Primjena prema bilo kojem od patentnih zahtjeva 1-5, naznačena time što je navedeni gaboksadol kristalan.
7. Primjena prema bilo kojem od patentnih zahtjeva 1-6, naznačena time što je navedena kompozicija namijenjena za liječenje čovjeka koji ima depresiju.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48301903P | 2003-06-25 | 2003-06-25 | |
DKPA200300956 | 2003-06-25 | ||
US53512304P | 2004-01-07 | 2004-01-07 | |
DKPA200400016 | 2004-01-07 | ||
PCT/DK2004/000459 WO2004112786A2 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100276T1 true HRP20100276T1 (hr) | 2010-06-30 |
Family
ID=33545397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100276T HRP20100276T1 (hr) | 2003-06-25 | 2010-05-18 | Gaboksadol za liječenje depresije i drugih afektivnih poremećaja |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP1641456B1 (hr) |
JP (1) | JP2007508236A (hr) |
AT (1) | ATE459353T1 (hr) |
AU (1) | AU2004248890A1 (hr) |
BR (1) | BRPI0410857A (hr) |
CY (1) | CY1110046T1 (hr) |
DE (1) | DE602004025808D1 (hr) |
DK (1) | DK1641456T3 (hr) |
ES (1) | ES2341004T3 (hr) |
HR (1) | HRP20100276T1 (hr) |
IL (2) | IL172631A0 (hr) |
MX (1) | MXPA05013016A (hr) |
NZ (1) | NZ543586A (hr) |
PL (1) | PL1641456T3 (hr) |
PT (1) | PT1641456E (hr) |
SI (1) | SI1641456T1 (hr) |
WO (1) | WO2004112786A2 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005023256A1 (en) * | 2003-09-10 | 2005-03-17 | Merck Sharp & Dohme Limited | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
ES2515092T3 (es) | 2003-12-11 | 2014-10-29 | Sunovion Pharmaceuticals Inc. | Combinación de un sedante y un modulador neurotransmisor y métodos de mejorar la calidad del sueño y de tratar la depresión |
GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
WO2005079851A2 (en) | 2004-02-18 | 2005-09-01 | Sepracor, Inc. | Dopamine-agonist combination therapy with sedatives for improving sleep quality |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
WO2006083682A2 (en) | 2005-01-28 | 2006-08-10 | H.Lundbeck A/S | Polymorphic forms of a gabaa agonist |
WO2006118897A1 (en) * | 2005-04-29 | 2006-11-09 | H.Lundbeck A/S | Acid and base salt forms of gaboxadol |
TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
JP2012501301A (ja) * | 2008-09-01 | 2012-01-19 | ハー・ルンドベック・アクチエゼルスカベット | ガボキサドールおよびpat1阻害薬またはoat阻害薬を含む医薬組成物 |
WO2016150953A1 (en) | 2015-03-24 | 2016-09-29 | H. Lundbeck A/S | Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol |
AU2017363598A1 (en) * | 2016-11-22 | 2019-05-23 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with flupirtine |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
EP3761979A4 (en) * | 2018-04-06 | 2021-06-30 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT SUBSTANCE ABUSE |
US10765666B2 (en) | 2018-09-20 | 2020-09-08 | Ovid Therapeutics Inc | Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering |
CA3120856A1 (en) | 2018-11-21 | 2020-05-28 | Certego Therapeutics, Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
CN114072154B (zh) * | 2018-11-21 | 2024-03-08 | 塞迪戈Abc有限责任公司 | 用于治疗精神障碍的加波沙朵和锂的组合物 |
US11690829B2 (en) | 2018-12-17 | 2023-07-04 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
KR20220114572A (ko) | 2019-12-18 | 2022-08-17 | 오비드 테라퓨틱스 인크. | 1p36 결실 증후군의 치료적 치료를 위한 가복사돌 |
WO2021236876A2 (en) | 2020-05-20 | 2021-11-25 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
AR031473A1 (es) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide |
US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
AU2002338855B2 (en) | 2001-05-21 | 2007-08-16 | H. Lundbeck A/S | Granular preparations of gaboxadol |
-
2004
- 2004-06-25 ES ES04738956T patent/ES2341004T3/es active Active
- 2004-06-25 PT PT04738956T patent/PT1641456E/pt unknown
- 2004-06-25 DE DE602004025808T patent/DE602004025808D1/de active Active
- 2004-06-25 SI SI200431414T patent/SI1641456T1/sl unknown
- 2004-06-25 EP EP04738956A patent/EP1641456B1/en active Active
- 2004-06-25 NZ NZ543586A patent/NZ543586A/en unknown
- 2004-06-25 AU AU2004248890A patent/AU2004248890A1/en not_active Abandoned
- 2004-06-25 MX MXPA05013016A patent/MXPA05013016A/es active IP Right Grant
- 2004-06-25 WO PCT/DK2004/000459 patent/WO2004112786A2/en active Application Filing
- 2004-06-25 JP JP2006515735A patent/JP2007508236A/ja active Pending
- 2004-06-25 DK DK04738956.4T patent/DK1641456T3/da active
- 2004-06-25 BR BRPI0410857-4A patent/BRPI0410857A/pt not_active IP Right Cessation
- 2004-06-25 AT AT04738956T patent/ATE459353T1/de not_active IP Right Cessation
- 2004-06-25 PL PL04738956T patent/PL1641456T3/pl unknown
- 2004-06-25 EP EP09173892A patent/EP2145620A3/en not_active Withdrawn
-
2005
- 2005-12-15 IL IL172631A patent/IL172631A0/en unknown
-
2009
- 2009-11-12 IL IL202106A patent/IL202106A0/en unknown
-
2010
- 2010-05-14 CY CY20101100433T patent/CY1110046T1/el unknown
- 2010-05-18 HR HR20100276T patent/HRP20100276T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004112786A3 (en) | 2005-04-14 |
CY1110046T1 (el) | 2015-01-14 |
DK1641456T3 (da) | 2010-06-21 |
IL172631A0 (en) | 2006-04-10 |
BRPI0410857A (pt) | 2006-07-04 |
DE602004025808D1 (de) | 2010-04-15 |
EP2145620A2 (en) | 2010-01-20 |
EP2145620A3 (en) | 2010-03-17 |
JP2007508236A (ja) | 2007-04-05 |
AU2004248890A1 (en) | 2004-12-29 |
MXPA05013016A (es) | 2006-03-02 |
EP1641456A2 (en) | 2006-04-05 |
EP1641456B1 (en) | 2010-03-03 |
SI1641456T1 (sl) | 2010-06-30 |
ATE459353T1 (de) | 2010-03-15 |
WO2004112786A2 (en) | 2004-12-29 |
PL1641456T3 (pl) | 2010-08-31 |
ES2341004T3 (es) | 2010-06-14 |
NZ543586A (en) | 2009-07-31 |
IL202106A0 (en) | 2010-06-16 |
PT1641456E (pt) | 2010-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100276T1 (hr) | Gaboksadol za liječenje depresije i drugih afektivnih poremećaja | |
MX2009011755A (es) | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. | |
SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
BR0008060A (pt) | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica | |
ATE414519T1 (de) | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit | |
HRP20050253B1 (hr) | Diaril eteri kao opioid antagonisti opioidnih receptora | |
WO2007038112A3 (en) | Combination of rosiglitazone and donepezil for improvement of cognitive function | |
HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
BR0215148A (pt) | Composições farmacêuticas de agonista parcial 5ht4 | |
ES2340502T3 (es) | Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad. | |
BR0314488A (pt) | Composto, composição farmacêutica e métodos de tratamento | |
RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
MXPA06000705A (es) | Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos. | |
MX2007012300A (es) | Uso de nefopam y analogos del mismo para el tratamiento de un sindrome caracterizado por dolor cronico y fatiga. | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
TW200603816A (en) | Risedronate compositions and their methods of use | |
IL168704A (en) | Calcilytic compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disease or disorder characterized by abnormal bone or mineral homeostasis | |
MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. | |
WO2007062862A3 (en) | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders | |
WO2005121074A3 (en) | Processes for the preparation of sertraline hydrochloride | |
HRP20090102T3 (hr) | Poboljšana farmaceutska smjesa koja sadrži ace inhibitor i postupak za njeno pripravljanje | |
BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios |